Your browser doesn't support javascript.
loading
Developmental or Procedural Vena Cava Interruption and Venous Thromboembolism: A Review.
Bikdeli, Behnood; Sadeghipour, Parham; Lou, Junyang; Bejjani, Antoine; Khairani, Candrika D; Rashedi, Sina; Lookstein, Robert; Lansky, Alexandra; Vedantham, Suresh; Sobieszczyk, Piotr; Mena-Hurtado, Carlos; Aghayev, Ayaz; Henke, Peter; Mehdipoor, Ghazaleh; Tufano, Antonella; Chatterjee, Saurav; Middeldorp, Saskia; Wasan, Suman; Bashir, Riyaz; Lang, Irene M; Shishehbor, Mehdi H; Gerhard-Herman, Marie; Giri, Jay; Menard, Matthew T; Parikh, Sahil A; Mazzolai, Lucia; Moores, Lisa; Monreal, Manuel; Jimenez, David; Goldhaber, Samuel Z; Krumholz, Harlan M; Piazza, Gregory.
Afiliación
  • Bikdeli B; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Sadeghipour P; Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lou J; YNHH/Yale Center for Outcomes Research and Evaluation (CORE), New Haven, Connecticut.
  • Bejjani A; Cardiovascular Research Foundation (CRF), New York, New York.
  • Khairani CD; Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Rashedi S; Clinical Trial Center, Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Lookstein R; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Lansky A; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Vedantham S; Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Sobieszczyk P; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Mena-Hurtado C; Thrombosis Research Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Aghayev A; Rajaie Cardiovascular, Medical, and Research Center, Iran University of Medical Sciences, Tehran, Iran.
  • Henke P; Division of Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Mehdipoor G; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Tufano A; Mallinckrodt Institute of Radiology, Washington University in St. Louis, St. Louis, Missouri.
  • Chatterjee S; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Middeldorp S; Section of Cardiovascular Medicine, Yale School of Medicine, New Haven, Connecticut.
  • Wasan S; Cardiovascular Imaging Program, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Bashir R; Section of Vascular Surgery, Department of Surgery, University of Michigan, Ann Arbor, Michigan.
  • Lang IM; Cardiovascular Research Foundation (CRF), New York, New York.
  • Shishehbor MH; Center for Evidence-based Imaging, Brigham and Women's Hospital, Boston, Massachusetts.
  • Gerhard-Herman M; Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.
  • Giri J; Division of Cardiology, Department of Medicine, Zucker School of Medicine, New York, New York.
  • Menard MT; Department of Internal Medicine, Radboud Institute of Health Sciences (RIHS), Radboud University Medical Center, Nijmegen, The Netherlands.
  • Parikh SA; University of North Carolina, Chapel Hill, North Carolina.
  • Mazzolai L; Departement of Cardiovascular Diseases, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.
  • Moores L; Department of Internal Medicine II, Cardiology and Center of Cardiovascular Medicine, Medical University of Vienna, Vienna, Austria.
  • Monreal M; University Hospitals Heath System, Harrington Heart and Vascular Institute, Cleveland, Ohio.
  • Jimenez D; Cardiovascular Medicine Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Goldhaber SZ; Penn Cardiovascular Outcomes, Quality, and Evaluative Research Center, Cardiovascular Division, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Krumholz HM; Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
  • Piazza G; Cardiovascular Research Foundation (CRF), New York, New York.
Semin Thromb Hemost ; 50(6): 851-865, 2024 Sep.
Article en En | MEDLINE | ID: mdl-38176425
ABSTRACT
The inferior vena cava (IVC) and superior vena cava are the main conduits of the systemic venous circulation into the right atrium. Developmental or procedural interruptions of vena cava might predispose to stasis and deep vein thrombosis (DVT) distal to the anomaly and may impact the subsequent rate of pulmonary embolism (PE). This study aimed to review the various etiologies of developmental or procedural vena cava interruption and their impact on venous thromboembolism. A systematic search was performed in PubMed according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines per each clinical question. For management questions with no high-quality evidence and no mutual agreements between authors, Delphi methods were used. IVC agenesis is the most common form of congenital vena cava interruption, is associated with an increased risk of DVT, and should be suspected in young patients with unexpected extensive bilateral DVT. Surgical techniques for vena cava interruption (ligation, clipping, and plication) to prevent PE have been largely abandoned due to short-term procedural risks and long-term complications, although survivors of prior procedures are occasionally encountered. Vena cava filters are now the most commonly used method of procedural interruption, frequently placed in the infrarenal IVC. The most agreed-upon indication for vena cava filters is for patients with acute venous thromboembolism and coexisting contraindications to anticoagulation. Familiarity with different forms of vena cava interruption and their local and systemic adverse effects is important to minimize complications and thrombotic events.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tromboembolia Venosa Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Semin Thromb Hemost Año: 2024 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Tromboembolia Venosa Tipo de estudio: Guideline Límite: Humans Idioma: En Revista: Semin Thromb Hemost Año: 2024 Tipo del documento: Article